Ruchir N Karmali1,2,3,4, Christopher Bush1, Sudha R Raman1,2, Cynthia I Campbell4, Asheley C Skinner1,2, Andrew W Roberts5,6. 1. Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA. 2. Duke Clinical Research Institute, Duke University, Durham, NC, USA. 3. Department of Health Policy and Management, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA. 4. Division of Research, Kaiser Permanente North California, Oakland, CA, USA. 5. Department of Population Health, University of Kansas Medical Center, Kansas City, KS, USA. 6. Department of Anesthesiology, University of Kansas Medical Center, Kansas City, KS, USA.
Abstract
PURPOSE: This review sought to (a) describe definitions of long-term opioid therapy (LTOT) outcome measures, and (b) identify the predictors associated with the transition from short-term opioid use to LTOT for opioid-naïve individuals. METHODS: We conducted a systematic review of the peer-reviewed literature (January 2007 to July 2018). We included studies examining opioid use for more than 30 days. We classified operationalization of LTOT based on criteria used in the definitions. We extracted LTOT predictors from multivariate models in studies of opioid-naïve individuals. RESULTS: The search retrieved 5,221 studies, and 34 studies were included. We extracted 41 unique variations of LTOT definitions. About 36% of definitions required a cumulative duration of opioid use of 3 months. Only 17% of definitions considered consecutive observation periods, 27% used days' supply, and no definitions considered dose. We extracted 76 unique predictors of LTOT from seven studies of opioid-naïve patients. Common predictors included pre-existing comorbidities (21.1%), non-opioid prescription medication use (13.2%), substance use disorders (10.5%), and mental health disorders (10.5%). CONCLUSIONS: Most LTOT definitions aligned with the chronic pain definition (pain more than 3 months), and used cumulative duration of opioid use as a criterion, although most did not account for consistent use. Definitions were varied and rarely accounted for prescription characteristics, such as days' supply. Predictors of LTOT were similar to known risk factors of opioid abuse, misuse, and overdose. As LTOT becomes a central component of quality improvement efforts, researchers should incorporate criteria to identify consistent opioid use to build the evidence for safe and appropriate use of prescription opioids.
PURPOSE: This review sought to (a) describe definitions of long-term opioid therapy (LTOT) outcome measures, and (b) identify the predictors associated with the transition from short-term opioid use to LTOT for opioid-naïve individuals. METHODS: We conducted a systematic review of the peer-reviewed literature (January 2007 to July 2018). We included studies examining opioid use for more than 30 days. We classified operationalization of LTOT based on criteria used in the definitions. We extracted LTOT predictors from multivariate models in studies of opioid-naïve individuals. RESULTS: The search retrieved 5,221 studies, and 34 studies were included. We extracted 41 unique variations of LTOT definitions. About 36% of definitions required a cumulative duration of opioid use of 3 months. Only 17% of definitions considered consecutive observation periods, 27% used days' supply, and no definitions considered dose. We extracted 76 unique predictors of LTOT from seven studies of opioid-naïve patients. Common predictors included pre-existing comorbidities (21.1%), non-opioid prescription medication use (13.2%), substance use disorders (10.5%), and mental health disorders (10.5%). CONCLUSIONS: Most LTOT definitions aligned with the chronic pain definition (pain more than 3 months), and used cumulative duration of opioid use as a criterion, although most did not account for consistent use. Definitions were varied and rarely accounted for prescription characteristics, such as days' supply. Predictors of LTOT were similar to known risk factors of opioid abuse, misuse, and overdose. As LTOT becomes a central component of quality improvement efforts, researchers should incorporate criteria to identify consistent opioid use to build the evidence for safe and appropriate use of prescription opioids.
Authors: Andrew J Pugely; Nicholas A Bedard; Piyush Kalakoti; Nathan R Hendrickson; Jamal N Shillingford; Joseph L Laratta; Comron Saifi; Ronald A Lehman; K Daniel Riew Journal: Spine J Date: 2018-04-10 Impact factor: 4.166
Authors: Eric S Johnson; Barbara A Bartman; Becky A Briesacher; Neil S Fleming; Tobias Gerhard; Cynthia J Kornegay; Parivash Nourjah; Brian Sauer; Glen T Schumock; Art Sedrakyan; Til Stürmer; Suzanne L West; Sebastian Schneeweiss Journal: Pharmacoepidemiol Drug Saf Date: 2012-10-01 Impact factor: 2.890
Authors: Richard A Deyo; Sara E Hallvik; Christi Hildebran; Miguel Marino; Eve Dexter; Jessica M Irvine; Nicole O'Kane; Joshua Van Otterloo; Dagan A Wright; Gillian Leichtling; Lisa M Millet Journal: J Gen Intern Med Date: 2016-08-02 Impact factor: 5.128
Authors: Rabia Qureshi; Brian Werner; Varun Puvanesarajah; Jason A Horowitz; Amit Jain; Daniel Sciubba; Francis Shen; Hamid Hassanzadeh Journal: World Neurosurg Date: 2018-01-31 Impact factor: 2.104
Authors: Jessica M Franklin; William H Shrank; Juliana Pakes; Gabriel Sanfélix-Gimeno; Olga S Matlin; Troyen A Brennan; Niteesh K Choudhry Journal: Med Care Date: 2013-09 Impact factor: 2.983
Authors: James Dahlhamer; Jacqueline Lucas; Carla Zelaya; Richard Nahin; Sean Mackey; Lynn DeBar; Robert Kerns; Michael Von Korff; Linda Porter; Charles Helmick Journal: MMWR Morb Mortal Wkly Rep Date: 2018-09-14 Impact factor: 17.586
Authors: Shabbar I Ranapurwala; Rebecca B Naumann; Anna E Austin; Nabarun Dasgupta; Stephen W Marshall Journal: Pharmacoepidemiol Drug Saf Date: 2018-06-03 Impact factor: 2.890
Authors: Hemalkumar B Mehta; Yong-Fang Kuo; Mukaila A Raji; Jordan Westra; Cynthia Boyd; G Caleb Alexander; James S Goodwin Journal: J Am Med Dir Assoc Date: 2021-05-19 Impact factor: 4.669
Authors: Jennifer L Kuntz; John F Dickerson; Jennifer L Schneider; Alison J Firemark; Dea Papajorgji-Taylor; Matthew Slaughter; Katherine R Reese; Lou Ann Thorsness; Mark D Sullivan; Lynn L Debar; David H Smith Journal: J Am Pharm Assoc (2003) Date: 2021-01-21
Authors: Bethany L DiPrete; Shabbar I Ranapurwala; Courtney N Maierhofer; Naoko Fulcher; Paul R Chelminski; Christopher L Ringwalt; Timothy J Ives; Nabarun Dasgupta; Vivian F Go; Brian W Pence Journal: JAMA Netw Open Date: 2022-04-01
Authors: Helena De Sola; María Dueñas; Alejandro Salazar; Patricia Ortega-Jiménez; Inmaculada Failde Journal: Front Pharmacol Date: 2020-11-18 Impact factor: 5.810
Authors: Ian C Scott; James Bailey; Christopher R White; Christian D Mallen; Sara Muller Journal: Rheumatology (Oxford) Date: 2022-08-03 Impact factor: 7.046
Authors: GYeon Oh; Emily S Brouwer; Erin L Abner; David W Fardo; Patricia R Freeman; Chris Delcher; Daniela C Moga Journal: Sci Rep Date: 2021-07-29 Impact factor: 4.379